475086-01-2

If you are looking for a supplier or manufacturer of Selexipag(CAS: 475086-01-2), please contact us. For more than 10 years, we have been focusing on custom synthesis and large-scale manufacturing of organic compound products. We can provide high-quality compounds and good service to customers all over the world. Now, we also hope to meet your needs for Selexipag(CAS: 475086-01-2)and other compounds.

Send Inquiry

Product Description

Name	Selexipag
Synonyms	UNII-5EXC0E384L;Selexipag (JAN/USAN/INN);2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide;Selexipag [USAN:INN];2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide;NS-304;ACT-293987;MRE-304;2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide;Uptravi (brand name)
Molecular Formula	C₂₆H₃₂N₄O₄S
Molecular Weight	496.62200
CAS Number	475086-01-2
purity	≥98%
Storage conditions	Sealed in dry,2-8°C

Applications：

Selexipag (brand name Uptravi) (CAS: 475086-01-2) is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.

Hot Tags: